Rocket Scores $180 Million Cash Boost – Extends Runway to 2028 for Heart Gene Therapies
Rocket Pharma sold an FDA voucher for $180M cash, boosting funds without dilution and extending runway to 2028 for heart gene therapies.
NOTRELOAD AI
Corning Sinks After Q1 Beat as Softer Q2 Guidance Disappoints Investors
Corning beat Q1 estimates but gave weak Q2 outlook, so shares fell despite strong year-to-date gains.
Erasca Stock Crashes on Patient Death — But Analysts Call the Selloff Overdone
Erasca stock fell after a patient died in a cancer drug trial. Analysts say it’s likely a rare case, drug still shows promise.
HyBryte Skin Cancer Drug Fails Key Test – Soligenix FLASH2 Trial Halted
Soligenix stopped HyBryte CTCL trial early as it didn’t work well, though it was safe; company will review data and options.
Coca-Cola Raises Full-Year Profit Forecast After Strong Q1 2026 Beat
Coca-Cola beat earnings, grew sales and profit, raised its outlook, and is selling more drinks worldwide.
UPS Profit Falls in Q1 as It Ditches Amazon Deliveries — But Growth Returns Soon
UPS profits fell in Q1 2026 after cutting Amazon deliveries, but beat forecasts and expects growth soon from cost cuts and healthcare focus.